321 related articles for article (PubMed ID: 10977391)
1. Mirtazapine. A pharmacoeconomic review of its use in depression.
Holm KJ; Jarvis B; Foster RH
Pharmacoeconomics; 2000 May; 17(5):515-34. PubMed ID: 10977391
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in austria.
Brown MC; Nimmerrichter AA; Guest JF
Eur Psychiatry; 1999 Jul; 14(4):230-44. PubMed ID: 10572352
[TBL] [Abstract][Full Text] [Related]
3. Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK.
Borghi J; Guest JF
Eur Psychiatry; 2000 Sep; 15(6):378-87. PubMed ID: 11004733
[TBL] [Abstract][Full Text] [Related]
4. Mirtazapine: a review of its use in major depression.
Holm KJ; Markham A
Drugs; 1999 Apr; 57(4):607-31. PubMed ID: 10235695
[TBL] [Abstract][Full Text] [Related]
5. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
[TBL] [Abstract][Full Text] [Related]
6. Mirtazapine versus selective serotonin reuptake inhibitors.
Thompson C
J Clin Psychiatry; 1999; 60 Suppl 17():18-22; discussion 46-8. PubMed ID: 10446737
[TBL] [Abstract][Full Text] [Related]
7. Fluoxetine. A pharmacoeconomic review of its use in depression.
Wilde MI; Benfield P
Pharmacoeconomics; 1998 May; 13(5 Pt 1):543-61. PubMed ID: 10180753
[TBL] [Abstract][Full Text] [Related]
8. A review of the pharmacological and clinical profile of mirtazapine.
Anttila SA; Leinonen EV
CNS Drug Rev; 2001; 7(3):249-64. PubMed ID: 11607047
[TBL] [Abstract][Full Text] [Related]
9. A risk-benefit assessment of mirtazapine in the treatment of depression.
Kasper S; Praschak-Rieder N; Tauscher J; Wolf R
Drug Saf; 1997 Oct; 17(4):251-64. PubMed ID: 9352961
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data.
Kasper S
Int Clin Psychopharmacol; 1995 Dec; 10 Suppl 4():25-35. PubMed ID: 8930007
[TBL] [Abstract][Full Text] [Related]
11. Does mirtazapine have a more rapid onset than SSRIs?
Quitkin FM; Taylor BP; Kremer C
J Clin Psychiatry; 2001 May; 62(5):358-61. PubMed ID: 11411818
[TBL] [Abstract][Full Text] [Related]
12. Spotlight on the pharmacoeconomics of escitalopram in depression.
Croom KF; Plosker GL
CNS Drugs; 2004; 18(7):469-73. PubMed ID: 15139801
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients.
Versiani M; Moreno R; Ramakers-van Moorsel CJ; Schutte AJ;
CNS Drugs; 2005; 19(2):137-46. PubMed ID: 15697327
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine.
Kasper S
J Clin Psychopharmacol; 1997 Apr; 17 Suppl 1():19S-28S. PubMed ID: 9090574
[TBL] [Abstract][Full Text] [Related]
15. Mirtazapine: a review of its use in major depression and other psychiatric disorders.
Croom KF; Perry CM; Plosker GL
CNS Drugs; 2009; 23(5):427-52. PubMed ID: 19453203
[TBL] [Abstract][Full Text] [Related]
16. Are selective serotonin re-uptake inhibitors associated with an increased risk of self-harm by antidepressant overdose?
Bateman DN; Chick J; Good AM; Kelly CA; Masterton G
Eur J Clin Pharmacol; 2004 May; 60(3):221-4. PubMed ID: 15083251
[TBL] [Abstract][Full Text] [Related]
17. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.
Peveler R; Kendrick T; Buxton M; Longworth L; Baldwin D; Moore M; Chatwin J; Goddard J; Thornett A; Smith H; Campbell M; Thompson C
Health Technol Assess; 2005 May; 9(16):1-134, iii. PubMed ID: 15876362
[TBL] [Abstract][Full Text] [Related]
18. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
Pallanti S; Quercioli L; Bruscoli M
J Clin Psychiatry; 2004 Oct; 65(10):1394-9. PubMed ID: 15491244
[TBL] [Abstract][Full Text] [Related]
19. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.
Wheatley DP; van Moffaert M; Timmerman L; Kremer CM
J Clin Psychiatry; 1998 Jun; 59(6):306-12. PubMed ID: 9671343
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients.
Hong CJ; Hu WH; Chen CC; Hsiao CC; Tsai SJ; Ruwe FJ
J Clin Psychiatry; 2003 Aug; 64(8):921-6. PubMed ID: 12927007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
